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Abstract 
 
Objective(s) 
Bupropion is an atypical antidepressant that is widely used in smoke cessation under FDA approval. The 
study of synaptic effects of bupropion can help to finding out its mechanism(s) for stopping nicotine 
dependence. In this study the effects of perinatal bupropion on the population spike (PS)  amplitude of 
neonates were investigated.  
Materials and Methods  
Hippocampal slices were prepared from 18-25 days old rat pups. The experimental groups included control 
and bupropion-treated. Bupropion (40 mg/Kg, i.p.) was applied daily in perinatal period as pre-treatment. Due 
to the studying acute effects, bupropion was also added to the perfusion medium (10, 50, 200 µM for 30 min). 
The evoked PS was recorded from pyramidal layer of CA1 area, following stimulation of Schaffer collaterals.  
Results 
A concentration of 10 µM bupropion had no significant effects on the PS amplitude. The 50 µM concentration 
of bupropion reduced the amplitude of responses in 50% of the studied cases. At a concentration of 200 µM, 
the recorded PS amplitudes were reduced in all slices (n= 22). Amplitude was completely abolished in 8 out 
of the 22 slices. The decrease of the PS amplitude was found to be more in the non-pre-treated slices than in 
the pre-treated slices when both were perfused with 200 µM bupropion. 
Conclusion  
The results showed the perinatal exposure to bupropion and its acute effects while indicating that at 
concentrations of 50 and 200 µM bupropion reduced the PS amplitude. It was also found that there was 
evidence of synaptic adaptation in comparison of bupropion-treated and non-treated slices whereas they were 
both perfused with 200 µM. 
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Introduction 
The perinatal effects of antidepressants on 
central nervous system due to its common 
usage are important issues in neuroscience 
researches. Bupropion, an atypical 
antidepressant, improves the rate of successful 
smoking cessation. Clinical observations have 
reported that bupropion had beneficial effects 
on mood and withdrawal symptoms in 
smokers who were not trying to quit (1). The 
mechanism(s) of action of bupropion have not 
yet been completely clarified, but its 
effectiveness in smoking cessation appears to 
be independent of its antidepressant properties 
(2). Bupropion is a nicotinic acetylcholine 
receptor antagonist (nAChR) across a similar 
concentration range as that it can inhibit 
synaptic dopamine and noradrenalin 
transporter functions. The combined action for 
inhibiting of these transporters and nAChR 
may provide a good pharmaceutical drug for 
depression and smoke cessation (3, 4). It has 
also been shown that bupropion has no 
significant affinity for various types of 
receptors such as α or β-adrenoceptors, 5-HT, 
and dopamine or nicotinic receptors. 
Bupropion is a weak, but relatively selective, 
inhibitor of dopamine (DA) reuptake. Its 
potency as an inhibitor of norepinephrine (NE) 
reuptake is one-half of that of DA (4, 5). 
Electrophysiological evidences have shown, 
the drug induced a dose-dependent attenuation 
of the spontaneous firing rate of 
norepinephrine and an increase in 5-HT firing 
neurons, without altering dopaminergic 
neurons of mesolimbic/cortical regions after 
sustained administration. Bupropion can 
increase extracellular dopamine and 
norepinephrine concentrations in 
mesocorticolimbic areas without influencing 
serotonin concentration (6-8). The mesolimbic 
dopamine neurons play a major role during the 
addiction process. Nicotine acts directly on 
ventral tegmental area (VTA), dopamine 
neurons as well as the synaptic inputs to these 
neurons. Mansvelder et al reported that pre-
treatment of the brain slices with a clinically 
relevant concentration of bupropion decreases 
the effects of nicotine on DA neuron 
excitability (9). Nicotine is an addictive drug 
that has long-lasting and direct effects on 
synaptic functional in the hippocampus that 
may synergize with its effects on the ventral 
midbrain reward system (10). To advance our 
understanding of the therapeutic drugs for 
smoke cessation, we must seek a deeper 
understanding of cellular and molecular 
neurobiology as well as examining the 
function of relevant neural systems and extend 
our efforts in the effects of drugs on the 
pharmacology of the synapse. The knowledge 
of the cellular physiological responses of 
affected CNS neurons associates with changes 
of  abuse  drugs-induced  is  infancy.               
The previous focuses accomplished on 
alterations in cellular and synaptic plasticity in 
the VTA in response to addictive drugs               
(11-14). The synaptic plasticity can describe 
the mechanisms of nicotine addiction and 
learned associates within the context of 
tobacco usage. When a drug reduces nicotine 
dependency it also changes synaptic efficacy 
or synaptic plasticity. Over years of smoking, 
neuroadaptations occur and long term synaptic 
changes redound in the learned  behaviors        
(15, 16). Bupropion is an important drug for 
smoke cessation so it can alter the efficacy of 
synapses. The population spike (PS) amplitude 
is a good parameter for the studying of 
synaptic efficacy. The changes in the PS 
amplitude can help to explain changes in the 
synaptic efficacy. 
Some antidepressant drugs can affect LTP 
(long term potentiation) by changing the main 
features, such as PS amplitudes. Imipramine, 
desipramine and amitriptyline can block the 
induction of LTP in a concentration dependent 
manner (17). A study using treatment with 
fluoxetine (a selective serotonin reuptake 
inhibitor) reported that attenuation of LTP in 
the hippocampus dentate gyrus of the rats (18). 
Imipramine and (+) or (-) oxaprotiline had 
negligible effects on PS evoked by stratum 
radiatum stimulation. However, these two 
drugs can reduce postsynaptic excitability in 
low Ca
+2/ high Mg
+2 medium after an exposure 
of more than 15 min (19). The aim of the 
present study was to assess the effects of 
perinatal bupropion exposure on synaptically 
evoked PS in the CA1 region of neonatal 
hippocampal slices. 
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Materials and Methods 
Animals and Tissue preparation 
All procedures were approved by Ethical 
Committee of Urmia University of Medical 
Sciences (Iran) and done while observing 
animal rights. Female Wistar rats (Animal 
Unit, Pasture Institute, Iran 180–200 g) were 
housed at an ambient temperature (22-25 °C) 
under a controlled 12 hr light /dark cycle 
(8.00-20.00) and had free access to standard 
food and tap water. Experimental groups 
included: (1) the control group in which 
pregnant rats received no pre-treatment; and 
(2) the treatment group which received 
bupropion hydrochloride daily (DiPharma, 
Italy, donated by Dr. Abidi, Pharmaceutical 
Laboratories of Iran). It was dissolved in     
saline solution and was administered 
intraperitoneally (i.p.) at a volume of 40 mg/kg 
during pregnancy and the nursing  period        
(first day of pregnancy through to final pup 
dissociation). All administrations were 
performed between 08:00-10:00 hr. Briefly,   
rat pups between 18-25 days old were 
anaesthetized with ether and their brains were 
removed from the skull and were transmitted 
for 8-10 sec in a cooled artificial cerebrospinal 
fluid (ACSF at 4-6 °C) that was pre-bubbled 
with 5% CO2, 95% O2. Within 24 hr the last 
maternal injection, hippocampal slices were 
prepared  from  the  rat  pups  according                 
to standard protocols (20, 21) with a 
vibroslicer in thickness 400-450 µm (Campden 
Instruments UK, model MA752). The brain 
slices were immediately left to the holding 
chamber (Campden Instruments, model 
745PID) for 1 hr to recover at room 
temperature (22-24 °C). ACSF was composed 
of (in mM): NaCl 125, KCl 2.5, MgCl2 1, 
CaCl2 2.5, Glucose 20, NaH2PO4 1, NaHCO3 
25 (Merck, Germany), and pH= 7.3-7.4, 
osmolarity was 300±5 mosmol. Either a single 
slice or two slices were transferred into an 
interface recording chamber. They were then 
stabilized under a mesh and continuously 
submerged and superfused with carbogenated 
ACSF at 32±1 °C with the rate of 2 ml/min. 
 
Experimental procedure 
The positioning of the stimulation and 
recording electrodes was identified via light 
microscopy (×40). A borosilicate glass 
recording electrode was prepared using a 
microelectrode puller (Japanese, Narishige 
PC10) and filled with 1 M NaCl (resistance: 3-
10 MOhm) used to detect PS in the stratum 
pyramidal cell layer of CA1 region. After 
electrode insertion, test stimuli were generated 
by stimulator (Bioscience. UK, CSF8173) and 
isolated by high current isolator (A385, WPI, 
USA). The input-output (I/O) curve was 
estimated at 50% of maximum synaptic 
response. After calculation curve, the PS were 
evoked by constant stimulation (duration 0.1 
ms, 15 V) with an insulated bipolar tungsten 
electrode (tip diameter 0.05 mm) placed in the 
CA3 area of the Schaffer collateral pathway. 
Amplified signals digitized using a laboratory 
interface (ITC 16, Instrutech, Great Neck, NY, 
and USA) and then stored with Patchmaster 
(HEKA Electronic, Dr Schulze GmbH, 
Germany, ver 2.13) software on a Pentium IV 
PC. Recorded signals analyzed on-line with 
Patchmaster and off-line with Fitmaster 
(HEKA Electronic, Dr Schulze GmbH, 
Germany, ver 2.13). The responses were 
acquired and then bupropion was dissolved 
within ACSF solution at 10, 50 and 200 µM 
concentration and the slices were perfused for 
30 min via changing the perfusion medium by 
means of three-way taps. At a constant flow 
rate of 2 ml/min, about 60 sec were required 
until the drug reached the recording chamber. 
Each slice was only used for one 
concentration. The evoked responses were 
recorded while bupropion was present and 
then the perfusion solution was changed to 
normal (drug-free) ACSF again. The responses 
were recorded via the previously stated 
methods for another 240 min. 
 
Statistical analysis 
The evoked response parameters of percent PS 
amplitudes were measured before and after 
perfusion of bupropion. Data were normalized 
and the mean±SEM of n trials are shown. In 
each slice, amplitude of PS after perfusion was 
measured by using one way-repeated measured 
ANOVA and the Wilcoxon matched pairs 
signed rank test. Significant different points 
between amplitudes with interval of five min 
after perfusion related to before perfusion were  
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analyzed and different points revealed. 
Adjustment values after perfusion identified 
and average values between different slices 
were analyzed by using ANOVA (post hoc -
Tukey test) and correlated paired t-test. Also, 
Igor (ver 6.3, Wave metrics Inc USA) and           
GB-State (ver 5.0, Dynamic Microsystems, Inc 
USA) were used for data analysis.  
 
 
Results 
The  results  showed  that  concentration  of            
10  µM  did  not  reduce  the  PS  amplitudes          
(n= 7). Bupropion had negligible effects on PS 
evoked by stratum radiatum stimulation. When 
using at concentration of 50 µM and 30 min, 
the amplitudes were reduced in 50% of the 
cases (n= 8), average point to point showed 
that the perfusion bupropion could reduce 
evoked PS amplitude by 25%. Amplitude of 
PS reduced in the all treated slices (n= 22) 
which were perfused at 200 µM concentration 
of bupropion. Amplitude of PS was reduced in 
8 out of 22 slices to 100%, that is, the 
amplitude was abolished. Reduction of PS 
amplitudes was reversible during a wash out of 
30 min at 200 µM bupropion perfusion (n= 20, 
all slices= 22). In this group, average point to 
point showed that evoked PS amplitude was 
reduced by 65%. Using ANOVA test showed 
significant difference in PS amplitude 
comparison between these groups, the control 
group related to treated groups with perfusion 
at 50 µM of bupropion (P< 0.05) and at 
concentration of 200 µM (P< 0.01) (Figure 1). 
The amplitude of PS in the control group was 
fitted for baseline 100%. Perfusion at 200 µM 
of bupropion in the control (n= 15) and the 
bupropion pretreatment (n= 22) groups 
reduced the PS evoked responses. Changes of 
the PS amplitude are shown in Figure 2. 
Statistical comparison of PS amplitude by 
using repeated measurement ANOVA showed 
F2, 143 = 453/3,  and  average  PS  amplitudes        
had difference (P< 0.0001). There is a 
significant difference between analogous 
points from the two groups according to the 
Willcoxn rank sum/Mann-Whitney  u-test          
(P< 0.0001). Average statistical comparison 
in two groups by separated variance t-test 
showed that the averages of inner group had 
significant difference (P= 0.0002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison of the PS amplitude changes between 
the treated groups and control group. Amplitude of PS in the 
control group was fitted as 100%. Significant difference 
with the control group * P< 0.05; ** P< 0.01; ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Changes of average PS amplitude in 
bupropion-treated and non-treated slices which were 
both perfused with bupropion (200 µM). Amplitude of 
PS before bupropion perfusion was fitted as 100% for 
baseline. Records were taken every five min, first 5 
records are related to before perfusion and bupropion 
perfusion starting at initial time for 30 min. Upper traces 
show changes of population spike in the control group 
slice.  p< 0.0001; according to the Wilcoxon Rank 
Sum/Mann-Whitney u-test compared to analogous 
points from two groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Comparison of PS amplitude changes in the 
treated and control groups which were both perfused 
with 200 µM bupropion, *p< 0.05 comparison before 
perfusion in each group. #p< 0.05 comparison after 
perfusion related to the control group.  
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The decrease of PS amplitude in the control 
group was more than perinatal treated group 
(Figure 3). The control group showed decreased 
amplitude by 80% and with more samples had 
their amplitude abolished, but in the treated 
group there was 65% decrease and only 8 out of 
the 22 slices had their PS amplitude abolished. 
 
Discussion  
Massicotte  et al found that chronic 
administration of trimipramine (tricyclic 
antidepressant) caused a large reduction in the 
magnitude of LTP inducted in rats (22). 
Langosch and Walden found that acute 
trimipramine can decrease amplitude of PS 
dose dependently in guinea pig hippocampal 
slices (23). In this study, the authors found 
similar effects using bupropion. It was found 
that bupropion treatment of perinatal caused a 
subsequent decrease and potential abolishment 
of the PS of the synaptically evoked response in 
rat hippocampal slices. The decrease of the PS 
amplitude in non-pre-treated slices was more 
than that of the treated slices when they were 
both perfused with a 200 µM concentration of 
bupropion. 
The molecular mechanism(s) responsible for 
the antidepressants induced neuroplastic 
changes in the hippocampus circuits are not 
fully understood. Different neuronal pathways 
may cause chronic effects of antidepressant 
drugs in the hippocampal synaptic plasticity. 
However, excitatory amino acid receptors, 
corticosteroids levels, monoamine 
neurotransmitters, cAMP response element 
binding protein (CREB), neurotrophic factors 
and other cellular messengers all have the 
potential to interact with a consequence for 
neuronal connectivity in the hippocampus. 
Antidepressant administrations can evaluate 
brain-derived neurotrophic factor (BDNF) 
levels, probably via noradrenaline and 
serotonin receptors (24-26). Neurotrophic 
effects of antidepressant drugs could help to 
restore the neuronal connectivity by inducing 
neurogenesis and new neural circuits, 
however, they facilitated synaptic connectivity 
(24, 27). It is obvious that antidepressant 
administration has the potential to change 
excitatory amino acid mediated synaptic 
plasticity and related to molecular and cellular 
organization in the brain (24).  Long term 
antidepressant administrations may also lead 
to a sustained alteration in the intracellular 
signal transduction cascades which mediate 
the functions of G-protein-coupled receptors 
and which influence receptor desensitization 
(28). One of the molecular adaptation induced 
by antidepressant treatments in the strength of 
synaptic transmission in the hippocampus, was 
accomplished by the major mediator of 
synaptic plasticity: NMDA receptor. 
Chronic administrations of imipramine or 
citalopram demonstrated to produce  regional 
specific changes in expression of transcripts 
for N-methyl-D-aspartate receptor (NMDAR) 
subunits; also, it has been proposed that the 
ratio of NR2A / NR2B of NMDA receptor 
subunit controls the threshold for synaptic 
modifications by controlling Ca
+2  entry and 
intracellular signaling cascades. Although 
regulation of the NR2A / NR2B ratio is clearly 
a more important determinant of the attribute 
synaptic efficacy but it is certainly only one of 
several important factors that affect the 
developmental and experience-dependent 
attribute of synaptic efficacy (29). The effects 
of bupropion on expression of transcript for 
NMDA receptor subunits and in the strength 
of synaptic transmission are unknown. It is 
possible that changes in brain gene expression, 
which are elicited after chronic bupropion 
treatments, might underlie the drug induced 
neural plasticity related to with its clinical 
efficacy in smoke cessation.  
 Bobula et al reported that treatments with 
imipramine or citalopram induced a reduction 
in the amplitude ratio of pharmacologically 
isolated AMPA/kainate to NMDA receptor-
dependent components of field potentials. This 
occurred when they were evoked in layer II/III 
by stimulating of their underlying sites in   
layer V and was reduced the glutamatergic 
synaptic transmission in the cerebral cortex 
(30). The antidepressant administrations 
induce regulation of hippocampal synaptic 
neurotransmission by alteration of 
monoaminergic pathways projecting to the 
hippocampus (31). The level of synaptically 
released glutamate may change due to  
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antidepressants induced neuroadaptations 
changes in the presynaptic monoamine 
heteroreceptors located on glutamatergic 
terminals and/ or in the postsynaptic 
monoamine receptors (28). Bupropion, a 
nicotinic acetylcholine receptor antagonist, is 
able to inhibit nAChRs in soma and dendrite 
of pyramidal and interneuron cells. It also 
affects GLU/GABA release. The balance of 
these two neurotransmitters can influence 
synaptic efficacy.    Intracellular calcium level 
regulates by excitatory amino acid receptors 
and it's determining synaptic responses such as 
evoked PS. It may be that antidepressant 
functional modulates this process in a number 
of ways, acting acutely through rapidly 
responsive excitatory amino acids systems, 
and chronically by inducing long term 
sustained changes in the cellular structure of 
hippocampus (32). Langosch and Walden 
suggested that the calcium antagonistic effects 
of Trimipramine may be responsible dose 
dependently for the inhibition of LTP and 
decrease PS amplitude as well as for its 
antidepressant action (23). Hippocampal 
configuration of GABAergic inhibitory 
interneuron has a major role in the 
synchronization of neuronal functional and is 
involved in the generation of large-scale 
network oscillations and has a direct influence 
on the integration of synaptic signals in the 
pyramidal cell (33). Bupropion may influence 
PS through interneurons. It seems likely that 
perikaryal synapses or interneurons could 
make the responses.  
At higher doses, the atypical antipsychotic 
clozapine inhibits the Schaffer-collateral 
evoked field potentials in the hippocampal 
slices (34). Acute clozapine also enhances the 
NMDA-mediated of glutamatergic synaptic 
responses in the striatal and the prefrontal 
cortex (PFC) slices and field potential 
responses  potentiates  in  the  hippocampus       
in vivo. In clozapine, the long-lasting 
potentiation of the NMDA component of 
evoked glutamatergic excitatory postsynaptic 
potentials (EPSPs) is dependent on dopamine 
D1 receptor modulation. (35). The bupropion 
effects of interaction of dopamine D1 and 
NMDA receptors, that it may be mediate 
NMDA complex of glutamatergic synaptic 
responses and those parameters of synaptic 
responses such as PS amplitude in the brain 
regions have not been studied. 
 
Conclusion 
There are some mechanisms involved in 
production of PS which can affect by perinatal 
exposure of bupropion. Perinatal bupropion 
exposure affected the dose dependant 
mechanism(s) involved in the adaptation of the 
synaptic efficiency. Other studies about 
synaptic effects of antidepressants postulated 
that some neurotransmitters such as dopamine, 
GABA and glutamate can mediate bupropion 
synaptic effects. 
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